Back

AURELIA

Bevacizumab Combined With Chemotherapy for Platinum- Resistant Recurrent Ovarian Cancer: The AURELIA Open- Label Randomized Phase III Trial

Date of Publication:

May 1, 2014

Pubmed Link:
https://pubmed.ncbi.nlm.nih.gov/24637997/
Hypothesis:

Does adding bevacizumab to chemotherapy  improve the efficacy of chemotherapy in patients with platinum-resistance recurrent ovarian cancer?

Control Arm(s):

Investigator's choice of paclitaxel, topotecan, or Doxil

Experimental Arm(s):

Investigator's choice of paclitaxel, topotecan, or Doxil

Bevacizumab 10mg/kg q2wks or 15mg/kg q3wks

Primary End Point:

PFS

Inclusion Criteria:

Recurrent ovarian cancer

<6 months from prior platinum therapy

Exclusion Criteria:

>2 prior chemotherapy regimen

Treatment refractory disease

History of bowel obstruction / GI perforation or fistula

Results:

Bev+chemo vs. chemo:

median PFS: 6.7mo vs. 3.4mo (SS)

ORR 30.9% vs. 12.6% (SS)

GI perforation: 2.2% in Bev+chemo arm

HTN grade 3+: 7% in Bev+chemo arm

Conclusions:

Adding bevacizumab to single-agent chemotherapy improves PFS in platinum-resistant recurrent ovarian cancer.

Reviewer:
Ross Harrison, OTF